Table 3:
Associations of log2-transformed biomarkers of immune activation with kidney failure with replacement therapy in AASK.
| Model | n | events | sTNFR1 | sTNFR2 | TNF-α | IFN-γ | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Hazard Ratio (95% CI) | p-value | Hazard Ratio (95% CI) | p-value | Hazard Ratio (95% CI) | p-value | Hazard Ratio (95% CI) | p-value | |||
| Model 0: Unadjusted | 500 | 161 | 8.10 (6.15, 10.66) | <0.001 | 5.09 (4.03, 6.43) | <0.001 | 1.88 (1.54, 2.29) | <0.001 | 1.11 (0.98, 1.25) | 0.10 |
| Model 1: Adjusted for age and sex | 500 | 161 | 7.44 (5.59, 9.89) | <0.001 | 4.63 (3.63, 5.91) | <0.001 | 1.69 (1.39, 2.07) | <0.001 | 1.08 (0.96, 1.22) | 0.19 |
| Model 2: Model 1 + systolic BP, BMI, and current smoking | 500 | 161 | 8.30 (6.06, 11.35) | <0.001 | 4.98 (3.82, 6.50) | <0.001 | 1.69 (1.39, 2.07) | <0.001 | 1.08 (0.96, 1.22) | 0.19 |
| Model 3: Model 2 + GFR | 500 | 161 | 4.90 (3.16, 7.62) | <0.001 | 2.76 (1.97, 3.86) | <0.001 | 1.31 (1.05, 1.64) | 0.02 | 1.09 (0.96, 1.23) | 0.18 |
| Model 4: Model 3 + log2(urine PCR) | 500 | 161 | 3.66 (2.31, 5.80) | <0.001 | 2.29 (1.60, 3.29) | <0.001 | 1.35 (1.07, 1.71) | 0.01 | 1.03 (0.91, 1.16) | 0.69 |
| Model 5: Model 4 + APOL1 risk status and European ancestry | 333 | 112 | 3.83 (2.21, 6.61) | <0.001 | 2.53 (1.63, 3.95) | <0.001 | 1.28 (0.97, 1.70) | 0.09 | 1.02 (0.88, 1.18) | 0.81 |
Hazard ratios are per 2-fold higher baseline level of each biomarker.
Abbreviations: BP=blood pressure; GFR=glomerular filtration rate; PCR=protein-to-creatinine ratio; sTNFR1=soluble tumor necrosis factor receptor 1; sTNFR2=soluble tumor necrosis factor receptor 2; TNF-α=tumor necrosis factor alpha; IFN-γ=interferon gamma.